comparemela.com

Chemotherapy Radiotherapy Immunotherapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AstraZeneca Shares Top FTSE 100 Index Risers After Tagrisso Gets U S Approval

By Ian Walker AstraZeneca shares are up and leading the FTSE 100 index risers after the company said that its lung-cancer treatment Tagrisso, together with.

United statesDave fredricksonIan walkerSouth americaArticle normalBiotechnology servicesHealthcare life sciencesPolitical general newsChemotherapy radiotherapy immunotherapyMedical conditionsMedical treatments proceduresEquity marketsCommodity financial market newsContent typesFactiva filtersC amp ampe exclusion filter

Ipsen Reports Positive Results in Late-Stage Trial of Cancer Drug Cabometyx

By Helena Smolak Ipsen's phase-three trial of prostate cancer drug Cabometyx yielded positive results, the company said late Monday. The French.

San franciscoUnited statesHelena smolakChristelle huguetAmerican societyClinical oncology genitourinary symposiumArticle normalCancer drugsHealthcare life sciencesSpecialized drugs medicationsNew products servicesResearch developmentCorporate industrial newsProducts servicesNew product service testingPolitical general news

Sanofi suffers major blow as its cutting-edge cancer drug disappoints in Phase III trials

French pharmaceuticals giant Sanofi on Thursday said it would be halting development of a promising cancer treatment after the cutting-edge candidate failed.

France generalUnited statesTusamitamab ravtansinDietmar bergerTusamitamab ravtansineArticle normalCancer drugsHealthcare life sciencesSpecialized drugs medicationsNew products servicesResearch developmentCorporate industrial newsProducts servicesNew product service testingPolitical general newsChemotherapy radiotherapy immunotherapy

Intensity Therapeutics Shares Double After Positive Data From Breast-Cancer Treatment Trial

By Chris Wack Intensity Therapeutics shares doubled to $9.09 after the company said it saw positive data from its Phase 2 trial of INT230-6 in patients with.

Chris wackArticle normalBiotechnology servicesCancer drugsHealthcare life sciencesSpecialized drugs medicationsResearch developmentCorporate industrial newsBreast cancerPolitical general newsChemotherapy radiotherapy immunotherapyDemographic healthMedical conditionsMedical treatments proceduresWomen amp 39s healthIntensity therapeutics

Bristol Myers Gets FDA Priority Review of Opdivo-Chemotherapy Combo in Bladder Cancer

By Colin Kellaher Bristol Myers Squibb won a priority review from the Food and Drug Administration for its application seeking expanded approval of a.

New yorkUnited statesBristol myersColin kellaherBristol myers squibbDrug administrationMyers squibbArticle normalCancer drugsHealthcare life sciencesSpecialized drugs medicationsRegulation government policyNew products servicesProduct service approvalsCorporate industrial newsProducts services

vimarsana © 2020. All Rights Reserved.